Seven Eight Capital’s Ascendis Pharma A/S ASND Stock Holding History

Seven Eight Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7,702	Closed	-$1.15M	–	44
2024 Q3	$1.15M	Sell	7,702 -8,174	-51%	-$1.1M	0.1%	348
2024 Q2	$2.17M	Buy	15,876 +11,279	+245%	+$1.53M	0.23%	118
2024 Q1	$695K	Sell	4,597 -14,039	-75%	-$2M	0.07%	388
2023 Q4	$2.35M	Buy	+18,636	New	+$1.86M	0.27%	92
2020 Q3	–	Sell	-2,200	Closed	-$325K	–	537
2020 Q2	$325K	Hold	2,200	–	–	0.24%	172
2020 Q1	$248K	Buy	+2,200	New	+$286K	0.06%	356

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Seven Eight Capital's ASND Position: Q4 2024 in Review

Seven Eight Capital sold out of Ascendis Pharma A/S (ASND) in Q4 2024, closing a stake of 7,702 shares — an estimated $1.15M sold.

Seven Eight Capital first reported a position in ASND in Q1 2020 and held it in 6 quarters. The position peaked at $2.35M in Q4 2023. 214 funds tracked by Wall St. Rank hold ASND as of Q4 2024.

Seven Eight Capital reported no remaining Ascendis Pharma A/S position as of Q4 2024 after selling out during the quarter.
Seven Eight Capital sold 7,702 Ascendis Pharma A/S shares in Q4 2024, an estimated $1.15M.
Seven Eight Capital first reported a position in Ascendis Pharma A/S in Q1 2020 and held it in 6 quarters.
Seven Eight Capital's Ascendis Pharma A/S position peaked at $2.35M in Q4 2023.
214 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.